Frequently Asked Questions

c Expand All C Collapse All

Subscription & licensing questions

Access to DIDB is provided via an annual subscription.

We can offer a free trial period to your organization in order to help you and your colleagues make the decision to subscribe to DIDB. Please contact us for more information.

Not at this time. Access to DIDB is granted to organizations via an annual subscription. The subscription allows for an unlimited number of users within an organization (or within a site for large organizations) to access DIDB.

DIDB is a research tool that was designed specifically for academic, pharmaceutical and regulatory scientists. DIDB is not intended as a primary clinical decision tool.

Questions about the data in DIDB

No, regulatory documents covered in DIDB are limited to NDAs and BLAs from the FDA.

DIDB includes both qualitative and quantitative human in vitro and clinical information related to various extrinsic and intrinsic factors. These include interacting co-medications, excipients, food products, herbals, tobacco, organ impairment, and genetics, that can affect drug exposure in humans.

The data come from the scientific literature and the NDA reviews of the FDA-approved products. The majority of articles are indexed by NCBI PubMed; however, some articles are obtained from Embase.

Most scientific publications are in English; therefore, the majority of data available in DIDB is from publications in English. However, some articles in DIDB are in other languages when published in native language of one of the team members, or when the (English) abstract provides sufficient information to include.

DIDB has detailed processes that have been developed over the last 20 years to ensure the most relevant data is captured in an unbiased manner by our curation process. The DIDB editorial team manually reviews the most relevant scientific journals, performs queries of NCBI PubMed, and verifies that relevant cited data are entered as well.

When information from an article or an NDA review is unclear, we check additional sources (e.g. clinicaltrials.gov for clinical DDI studies) or reach out to the authors of the article for clarification. Most of the time, we add comments within DIDB entries to explain possible discrepancies.

Daily. As soon as the DIDB entries have been reviewed and validated, they become available to subscribers immediately.

All of the DIDB editorial work is conducted in-house, within the Department of Pharmaceutics at the University of Washington School of Pharmacy. Our team is comprised of pharmaceutical scientists, pharmacists, and physicians with expertise in drug metabolism, transport, pharmacokinetics, drug interactions, and clinical pharmacology.

DIDB includes mainly metabolism- and transporter-based pharmacokinetic interactions. However, other mechanisms (e.g. absorption-based DDIs, pharmacogenetics, food effects, hepatic and renal impairment,…) are also covered. Pharmacodynamic interactions which cannot be explained by changes in drug or metabolite exposure are not included.

A citation is either a publication or an NDA/BLA review and often contains multiple in vitro and/or clinical studies. An in vitro study refers to an experiment, which may contain one or multiple entries, whereas a clinical study may have one of multiple experiments and each experiment entered in DIDB is referred to as an entry.

Yes, modeling and simulation data that are performed in lieu of clinical studies are included.

No, DIDB focuses only on human data (in vitro and clinical). Occasionally, data from humanized animal models may be included on a case-by-case basis.

Yes, DIDB contains in vitro and clinical data on biologics as objects (victims) and as precipitants (perpetrators).

Yes, DIDB contains in vitro and clinical DDI data on cannabinoids as objects (victims) and precipitants (perpetrators).

Yes, DIDB covers drug-drug, food-drug, and natural product-drug interactions.

Yes, DIDB contains in vitro and clinical DDI data mediated by non-CYP enzymes including, but not limited to, AOs, ADHs, AKRs, CESs, FMOs, MAOs, SULTs, and UGTs.

Yes, DIDB contains in vitro and clinical DDI data mediated by non-P-gp transporters including, but not limited to, BCRP, BSEP, CNTs, ENTs, MRPs, MATEs, OATs, OATPs, OCTs, OCTNs, and PEPTs.

DIDB application specific questions

The majority of biologics curated in DIDB belong to two therapeutic classes: immunomodulators biologics and neoplastic biologics. To retrieve data involving biologics belonging to these two therapeutic classes use the following query: Basic Queries > Therapeutic Class Queries > One Therapeutic Class (link) and type in one  of the therapeutic classes, select between objects or precipitants and “in vitro” and/or “in vivo”. Perform the same search for the other therapeutic class.

To find all biologics included in DIDB, go to Monographs > PK profiles (link). In the table review results select “yes” in the column of “Biologics”. Then you can use the DIDB queries to find data for any biologics included in this table but not belonging to the above therapeutic classes. 

Additionally, you can use the full text search function on the DIDB homepage (link) by typing in “biologics” to do a broad search from citations, monographs, and resources.

If you are interested in the newly approved biologics, you can access all data extracted from BLA reviews here

A quick way to find all the relevant in vitro and/or in vivo data involving food products is to use the following queries: Basic Queries > Therapeutic Class Queries > One Therapeutic Class, type or select “Food Products” from the drop-down list in the Therapeutic Class area, and select between Objects or Precipitants and in vitro and/or in vivo. In specific, the “Therapeutic Class (Advanced)” query on the same page can be used to search data with a focus on a specific mechanism.

To retrieve all data involving cannabinoids use the following queries: Basic Queries > Therapeutic Class Queries > One Therapeutic Class, and type in “Cannabinoids”, select between object or precipitant and “in vitro” and/or “in vivo”.

Yes, in vitro metabolism data can be searched based on a specific in vitro experimental system using the following query: Queries > Additional Queries > Other Queries. In the first subquery “System”, type or select the specific system of interest.

Some prodrugs may be detected in plasma along with their active moiety while others may not. Therefore, to search data involving prodrugs you need perform the search using both the prodrug and the active moiety as objects and precipitants. 

Currently in vitro transporter induction data is not included, but we are working on adding this module in the future when experimental protocols are well standardized and guidance from regulatory agencies is available. However, clinical transporter DDIs involving transporter induction are included in DIDB.

You can watch our tutorial documents and/or videos for tips (link). If you still have questions, feel free to contact us for assistance.

To retrieve the most recently published studies from literature use the following query: Additional queries > Citation queries (link) and type in the current Year and Month.

You can also access the list of the latest published citations from PubMed and Embase entered in DIDB, directly here.

To retrieve data about a specific pharmacokinetic parameter use the following query: Monographs (located at the top panel of DIDB homepage) > PK profiles (link). All compounds with different pharmacokinetic parameters will be presented in a table. You can use the table function, e.g., filter or re-order associated with each column, to generate the dataset of interest.

Yes. Fm in vitro and Fm in vivo are parameters presented in the compound PK profile. You can use the following query to find fm values of a specific compound if they are available: Monographs (located at the top panel of DIDB homepage) > PK profiles (link).